Aptose Biosciences Files Definitive Proxy for Acquisition by Hanmi Pharmaceutical, Sets Shareholder Vote

summarizeSummary

Aptose Biosciences Inc. has filed a definitive proxy statement for its acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., for C$2.41 per share in cash, with the shareholder meeting scheduled for March 31, 2026.

check_boxKey Events

• Acquisition Details Finalized

  HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all outstanding shares of Aptose Biosciences Inc. (not already owned by them) for C$2.41 per share in cash.

• Shareholder Meeting Scheduled

  A special meeting for shareholders to vote on the arrangement and a continuance resolution is scheduled for March 31, 2026.

• Board Unanimously Recommends Approval

  The Board unanimously recommends shareholders vote 'FOR' the acquisition, citing the offer's fairness and the company's distressed financial position.

• Fairness Opinion Provided

  Locust Walk Securities, LLC provided a formal valuation of C$1.00 to C$5.08 per share and a fairness opinion, concluding the C$2.41 offer is fair from a financial point of view.

auto_awesomeAnalysis

This filing provides the definitive terms for the previously announced acquisition of Aptose Biosciences by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd. The arrangement agreement was amended and restated on February 23, 2026, to extend the outside date for completion. The Board, based on a unanimous recommendation from its Transaction Committee and a fairness opinion from Locust Walk Securities, LLC, unanimously recommends shareholders approve the C$2.41 per share cash offer. The transaction is critical for Aptose, as the company faces a significant likelihood of insolvency if the arrangement is not completed, potentially leading to CCAA proceedings where shareholders may receive no consideration. The offer price represents a 28% premium to the 30-day volume-weighted average price.